Two cases of malignant effusion treated successfully by loco-regional administration of carboplatin

J. Takahashi, S. Kinomura, Y. Abe, S. Yoshioka, T. Yambe, S. Ono, H. Ito, H. Fukuda, K. Yamada, T. Sato

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

We encountered two cases of malignant effusion treated successfully by loco-regional administration of carboplatin (CBDCA). One case was a 60-year-old male showing recurrent non-small cell lung cancer (adenocarcinoma) with pericarditis carcinomatosa. A drainage from the pericardial cavity was performed and a total dose of 600 mg (single dose, 300 mg) of CBDCA was administered into the cavity. Malignant effusion disappeared and radiographic improvement was also observed. No pericardial effusion was observed for about 4 months after the loco-regional treatment, till he died of lung cancer. Another case was a 58-year-old male having invasive thymoma (mixed cell type) with pleuritis carcinomatosa. He received palliative radiation therapy and systemic cancer chemotherapy concurrently. As a loco-regional therapy, drainage from the pleural cavity was performed, and 300 mg of CBDCA and 10 KE of OK-432 were administered into the cavity. A remarkable reduction of pleural effusion was observed after the therapy. No increase of pleural effusion has been observed radiographically for about 18 months, and the patient is still alive with the tumor. The side effects due to loco-regional administration of CBDCA were quite tolerable in both cases.

Original languageEnglish
Pages (from-to)2817-2820
Number of pages4
JournalJapanese Journal of Cancer and Chemotherapy
Volume21
Issue number16
Publication statusPublished - 1994 Dec 1

Keywords

  • carboplatin
  • loco-regional administration
  • malignant effusion

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Two cases of malignant effusion treated successfully by loco-regional administration of carboplatin'. Together they form a unique fingerprint.

Cite this